Fluoxetine updated on 07-01-2025

Psychomotor developmental disorders/delay

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18251
R76596		 Suarez (Controls unexposed, discontinuers), 2022 Developmental Coordination Disorder - ≥ 2 dates with ICD-9 Dx 315.4 - At any age 2nd and/or 3rd trimester retrospective cohort (claims database) unexposed, sick Adjustment: Yes Monotherapy: no or not specified Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) 1.34 [0.74;2.43] 171/26,595   30/7,773 201 26,595
ref
S18252
R76604		 Suarez (Controls unexposed, general pop), 2022 Developmental Coordination Disorder - ≥ 2 dates with ICD-9 Dx 315.4 - At any age 2nd and/or 3rd trimester retrospective cohort (claims database) unexposed (general population or NOS) excluded Adjustment: Yes Monotherapy: no or not specified 1.44 [1.22;1.71]
excluded (control group) 		171/26,659   10,433/2,984,014 10,604 26,659
ref
S8015
R24402		 Nulman (Controls exposed to TCA), 2002 Psychomotor development IQ with Bayley Scales of Infant Development-II at 15 and 30 months of age throughout pregnancy prospective cohort exposed to other treatment, sick excluded Adjustment: No extrapolated (cont. endpoint) Monotherapy: SSRI only 1.44 [0.58;3.61]
excluded (control group) 		-/33   -/28 - 33
ref
S8016
R24407		 Nulman (Controls unexposed, disease free), 2002 Psychomotor development IQ with Bayley Scales of Infant Development-II at 15 and 30 months of age throughout pregnancy prospective cohort unexposed, disease free Adjustment: No extrapolated (cont. endpoint) Monotherapy: SSRI only 1.11 [0.39;3.14] -/33   -/18 - 33
ref
Total 2 studies 1.28 [0.76;2.14] 201 26,628
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Suarez (Controls unexposed, discontinuers), 2022Suarez, 2022 1 1.34[0.74; 2.43]20126,59575%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: lowROB mesure: criticalROB reporting: moderate Nulman (Controls unexposed, disease free), 2002Nulman, 2002 2 1.11[0.39; 3.14]-3325%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: lowROB mesure: lowROB reporting: moderate Total (2 studies) I2 = 0% 1.28[0.76; 2.14]20126,6280.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, discontinuers; 2: Controls unexposed, disease free;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.28[0.76; 2.14]20126,6280%NASuarez (Controls unexposed, discontinuers), 2022 Nulman (Controls unexposed, disease free), 2002 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.11[0.39; 3.15]-33 -NANulman (Controls unexposed, disease free), 2002 1 unexposed, sickunexposed, sick 1.34[0.74; 2.43]20126,595 -NASuarez (Controls unexposed, discontinuers), 2022 1 Tags Adjustment   - No  - No 1.11[0.39; 3.15]-33 -NANulman (Controls unexposed, disease free), 2002 1   - Yes  - Yes 1.34[0.74; 2.43]20126,595 -NASuarez (Controls unexposed, discontinuers), 2022 1 extrapolated (cont. endpoint)extrapolated (cont. endpoint) 1.11[0.39; 3.15]-33 -NANulman (Controls unexposed, disease free), 2002 1 Monotherapy   - no or not specified  - no or not specified 1.34[0.74; 2.43]20126,595 -NASuarez (Controls unexposed, discontinuers), 2022 1   - SSRI only  - SSRI only 1.11[0.39; 3.15]-33 -NANulman (Controls unexposed, disease free), 2002 1 Unexposed sick   - recent illness/treatment (during o ...  - recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) 1.34[0.74; 2.43]20126,595 -NASuarez (Controls unexposed, discontinuers), 2022 1 All studiesAll studies 1.28[0.76; 2.14]20126,6280%NASuarez (Controls unexposed, discontinuers), 2022 Nulman (Controls unexposed, disease free), 2002 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8015, 18252

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.43[1.21; 1.69]10,60426,6920%NASuarez (Controls unexposed, general pop), 2022 Nulman (Controls unexposed, disease free), 2002 2 unexposed, sick controlsunexposed, sick controls 1.34[0.74; 2.43]20126,595 -NASuarez (Controls unexposed, discontinuers), 2022 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.44[0.58; 3.59]-33 -NANulman (Controls exposed to TCA), 2002 10.510.01.0